Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Yesterday marked day one of the 2026 ASCO Genitourinary (GU) Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies that are ...

We report the clinical outcomes of a randomized trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer. This phase III, single ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in ...

Petros Grivas, MD, PhD, expresses great enthusiasm for the 2025 ASCO Annual Meeting, highlighting its wealth of clinical trial data, educational sessions, and real-world insights. He is particularly ...

Biomarker testing has the potential to streamline diagnosis, treatment planning, and anticipation of treatment risks, if done right.

Collapsing the very-low-risk category reflects broader acceptance of active surveillance for Gleason 6 disease, while PARP ...